Versavo 400 mg Inj

Bevacizumab is a monoclonal antibody that targets a protein called vascular endothelial growth factor (VEGF), which tumors rely on to stimulate the growth of new blood vessels, a process known as angiogenesis. By blocking VEGF, Bevacizumab helps limit the tumor's ability to develop the blood supply it needs for growth and spread, effectively helping to slow disease progression. It is commonly used in the treatment of metastatic colorectal cancer, non-small cell lung cancer, and advanced kidney cancer, typically in combination with chemotherapy or other targeted therapies as part of a comprehensive treatment plan. Bevacizumab is also used in certain other cancers, including some brain tumors and cervical cancer, expanding its role across various cancer types. This targeted approach represents an important advancement in cancer treatment, working through a different mechanism than traditional chemotherapy by specifically targeting the tumor's blood supply rather than directly attacking cancer cells. The medication is administered through intravenous infusion, typically in a hospital or specialized oncology setting, allowing healthcare providers to closely monitor the patient during and after administration. Regular monitoring, including blood pressure checks and periodic assessments of kidney function, is an important part of treatment to help ensure safety throughout the course of therapy. Many patients experience meaningful tumor response and improved disease management as part of a comprehensive cancer treatment plan involving Bevacizumab. As with all targeted cancer therapies, Bevacizumab injection should be administered under the close supervision of an experienced oncology healthcare team.